A recent study in liver cancer therapeutics has shown that targeting metabolic pathways and key regulators, such as STAM binding protein-like 1 (STAMBPL1), may offer novel strategies to alleviate the risk of hepatocellular carcinoma among those with chronic liver injury, including those affected by HIV and long-term HIV exposure [71]. The gene discussed is STAMBPL1; the disease is liver cancer.